The Uganda Virus Research Institute, In Collaboration With The International AIDS Vaccine Initiative And Targeted Genetics Corporation, Launches HIV/AIDS Vaccine Trial In Entebbe, Uganda

SEATTLE & ENTEBBE, Uganda--(BUSINESS WIRE)--Feb. 6, 2006--Targeted Genetics Corporation (Nasdaq:TGEN), The Uganda Virus Research Institute (UVRI), and the International AIDS Vaccine Initiative (IAVI), today announced the start of a Phase II clinical trial in Uganda to evaluate the safety and immunogenicity of tgAAC09, a preventive HIV/AIDS vaccine. This is the second IAVI-sponsored HIV vaccine trial to be conducted in Uganda.